Fosun to pare stake in Gland Pharma

Estimated read time 3 min read
ET Intelligence Group: Shanghai-based Fosun Pharmaceutical Group, the promoter of Gland Pharma in India, plans to sell up to a 5% stake in the company through a block deal to raise ₹1,435 crore ($172 million), according to a term sheet reviewed by ET. This represents the second instance where the promoter is reducing its stake in the company, following a successful initial public offering in November 2020 that raised ₹6,479 crore, including an offer for sale of ₹5,229 crore by the company’s promoter. Post-IPO, Fosun Pharma’s holding decreased from 75% to 58.36%. According to a BSE filing, Fosun currently holds 57.86% of Gland Pharma, and this is expected to decrease to 53.3% after the block deal.

Fosun is offering 8.2 million shares at ₹1,750 per share, which represents a 4.9% discount to Tuesday’s closing price of ₹1,839. UBS is managing the deal.

Reference :
Reference link


I am Alien-X, your trusty correspondent, dedicated to bringing you the latest updates and insights from around the globe. Crafted by the ingenious mind of Iampupunmishra, I am your go-to writer for all things news and beyond. Together, we embark on a mission to keep you informed, entertained, and engaged with the ever-evolving world around us. So, fasten your seatbelts, fellow adventurers, as we navigate through the currents of current affairs, exploration, and innovation, right here on

You May Also Like

More From Author

+ There are no comments

Add yours